Multifocal diffusion of a KPC-3 producing ST512 K. pneumoniae clone in Northern Italy

Roberta Migliavacca1, Elisabetta Nucleo, Sara Asticcioli

  • 1Department of Clinical Surgical Diagnostic and Paediatric Sciences, University of Pavia, Italy. r.miglia@unipv.it

The New Microbiologica
|February 26, 2013
PubMed

Insights

A Klebsiella pneumoniae ST512 clone carrying the blaKPC-3 gene has spread within and between hospitals in Northern Italy. This finding is crucial for understanding carbapenem-resistant Enterobacteriaceae (CRE) dissemination.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Genetics

Background:

  • Sequence Type 258 (ST258) Klebsiella pneumoniae is a major cause of carbapenem-resistant infections in Europe.
  • Carbapenemase-producing Klebsiella pneumoniae (KPC) are a significant public health threat.
  • Carbapenem-susceptibility in K. pneumoniae is often linked to the presence of blaKPC genes.

Purpose of the Study:

  • To investigate the occurrence of blaKPC genes in K. pneumoniae isolates from Northern Italy.
  • To describe the spread of a specific K. pneumoniae clone associated with blaKPC-3.

Main Methods:

  • Collection of 56 nonreplicate K. pneumoniae isolates with decreased carbapenem-susceptibility from 7 hospitals in Northern Italy.
  • Polymerase Chain Reaction (PCR) and sequencing to detect blaKPC-type genes.
  • Molecular typing to identify bacterial clones and track dissemination.

Main Results:

  • blaKPC2 and blaKPC-3 genes were detected in 10/56 and 5/56 isolates, respectively.
  • A K. pneumoniae ST512 clone harboring the blaKPC-3 gene was identified.
  • Evidence of both intra- and inter-hospital spread of this ST512 clone was observed.

Conclusions:

  • The K. pneumoniae ST512 clone carrying blaKPC-3 is circulating in Northern Italy.
  • This highlights the importance of molecular surveillance for tracking the spread of carbapenem-resistant K. pneumoniae.
  • Understanding clonal spread is essential for implementing effective control strategies against CRE.